Go Pro
→ Not oil. Not solar. Bigger. (From Behind the Markets) (Ad)tc pixel Free PRCT Stock Alerts

PROCEPT BioRobotics (PRCT) Competitors

PROCEPT BioRobotics logo
$19.22 0.00 (0.00%)
Closing price 04:00 PM Eastern
Extended Trading
$19.88 +0.66 (+3.43%)
As of 05:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

PRCT vs. LIVN, MMED, NVST, IRTC, and WRBY

Should you buy PROCEPT BioRobotics stock or one of its competitors? MarketBeat compares PROCEPT BioRobotics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with PROCEPT BioRobotics include LivaNova (LIVN), MiniMed Group (MMED), Envista (NVST), iRhythm Technologies (IRTC), and Warby Parker (WRBY). These companies are all part of the "medical equipment" industry.

How does PROCEPT BioRobotics compare to LivaNova?

LivaNova (NASDAQ:LIVN) and PROCEPT BioRobotics (NASDAQ:PRCT) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, risk, institutional ownership, profitability, earnings, dividends, media sentiment and valuation.

In the previous week, PROCEPT BioRobotics had 1 more articles in the media than LivaNova. MarketBeat recorded 2 mentions for PROCEPT BioRobotics and 1 mentions for LivaNova. LivaNova's average media sentiment score of 0.72 beat PROCEPT BioRobotics' score of -0.55 indicating that LivaNova is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
LivaNova
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
PROCEPT BioRobotics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Negative

97.6% of LivaNova shares are owned by institutional investors. Comparatively, 89.5% of PROCEPT BioRobotics shares are owned by institutional investors. 0.4% of LivaNova shares are owned by insiders. Comparatively, 4.0% of PROCEPT BioRobotics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

LivaNova has a net margin of 7.48% compared to PROCEPT BioRobotics' net margin of -31.82%. LivaNova's return on equity of 16.48% beat PROCEPT BioRobotics' return on equity.

Company Net Margins Return on Equity Return on Assets
LivaNova7.48% 16.48% 7.59%
PROCEPT BioRobotics -31.82%-27.70%-20.29%

LivaNova currently has a consensus price target of $81.38, indicating a potential upside of 2.73%. PROCEPT BioRobotics has a consensus price target of $37.27, indicating a potential upside of 93.93%. Given PROCEPT BioRobotics' higher probable upside, analysts clearly believe PROCEPT BioRobotics is more favorable than LivaNova.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
LivaNova
0 Sell rating(s)
4 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.60
PROCEPT BioRobotics
2 Sell rating(s)
7 Hold rating(s)
5 Buy rating(s)
1 Strong Buy rating(s)
2.33

PROCEPT BioRobotics has lower revenue, but higher earnings than LivaNova. PROCEPT BioRobotics is trading at a lower price-to-earnings ratio than LivaNova, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
LivaNova$1.39B3.13-$242.47M$1.9540.62
PROCEPT BioRobotics$308.05M3.55-$95.57M-$1.82N/A

LivaNova has a beta of 0.86, suggesting that its stock price is 14% less volatile than the broader market. Comparatively, PROCEPT BioRobotics has a beta of 0.87, suggesting that its stock price is 13% less volatile than the broader market.

Summary

LivaNova beats PROCEPT BioRobotics on 10 of the 17 factors compared between the two stocks.

How does PROCEPT BioRobotics compare to MiniMed Group?

PROCEPT BioRobotics (NASDAQ:PRCT) and MiniMed Group (NASDAQ:MMED) are both medical equipment companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, media sentiment, earnings, institutional ownership, dividends, profitability, risk and valuation.

PROCEPT BioRobotics has higher earnings, but lower revenue than MiniMed Group. MiniMed Group is trading at a lower price-to-earnings ratio than PROCEPT BioRobotics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
PROCEPT BioRobotics$308.05M3.55-$95.57M-$1.82N/A
MiniMed Group$3.10B1.53-$190.97M-$0.68N/A

In the previous week, MiniMed Group had 11 more articles in the media than PROCEPT BioRobotics. MarketBeat recorded 13 mentions for MiniMed Group and 2 mentions for PROCEPT BioRobotics. MiniMed Group's average media sentiment score of 0.09 beat PROCEPT BioRobotics' score of -0.55 indicating that MiniMed Group is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
PROCEPT BioRobotics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Negative
MiniMed Group
1 Very Positive mention(s)
0 Positive mention(s)
12 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

89.5% of PROCEPT BioRobotics shares are held by institutional investors. Comparatively, 19.7% of MiniMed Group shares are held by institutional investors. 4.0% of PROCEPT BioRobotics shares are held by insiders. Comparatively, 2.2% of MiniMed Group shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

PROCEPT BioRobotics presently has a consensus price target of $37.27, indicating a potential upside of 93.93%. MiniMed Group has a consensus price target of $21.33, indicating a potential upside of 26.08%. Given PROCEPT BioRobotics' higher possible upside, equities analysts clearly believe PROCEPT BioRobotics is more favorable than MiniMed Group.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
PROCEPT BioRobotics
2 Sell rating(s)
7 Hold rating(s)
5 Buy rating(s)
1 Strong Buy rating(s)
2.33
MiniMed Group
1 Sell rating(s)
2 Hold rating(s)
12 Buy rating(s)
0 Strong Buy rating(s)
2.73

MiniMed Group has a net margin of 0.00% compared to PROCEPT BioRobotics' net margin of -31.82%. MiniMed Group's return on equity of 0.00% beat PROCEPT BioRobotics' return on equity.

Company Net Margins Return on Equity Return on Assets
PROCEPT BioRobotics-31.82% -27.70% -20.29%
MiniMed Group N/A N/A N/A

Summary

MiniMed Group beats PROCEPT BioRobotics on 9 of the 16 factors compared between the two stocks.

How does PROCEPT BioRobotics compare to Envista?

Envista (NYSE:NVST) and PROCEPT BioRobotics (NASDAQ:PRCT) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, institutional ownership, valuation, earnings, dividends and media sentiment.

Envista presently has a consensus price target of $28.54, indicating a potential upside of 7.46%. PROCEPT BioRobotics has a consensus price target of $37.27, indicating a potential upside of 93.93%. Given PROCEPT BioRobotics' higher possible upside, analysts clearly believe PROCEPT BioRobotics is more favorable than Envista.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Envista
0 Sell rating(s)
10 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.38
PROCEPT BioRobotics
2 Sell rating(s)
7 Hold rating(s)
5 Buy rating(s)
1 Strong Buy rating(s)
2.33

In the previous week, PROCEPT BioRobotics had 2 more articles in the media than Envista. MarketBeat recorded 2 mentions for PROCEPT BioRobotics and 0 mentions for Envista. Envista's average media sentiment score of 1.02 beat PROCEPT BioRobotics' score of -0.55 indicating that Envista is being referred to more favorably in the media.

Company Overall Sentiment
Envista Positive
PROCEPT BioRobotics Negative

89.5% of PROCEPT BioRobotics shares are owned by institutional investors. 1.0% of Envista shares are owned by insiders. Comparatively, 4.0% of PROCEPT BioRobotics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Envista has a beta of 0.86, meaning that its share price is 14% less volatile than the broader market. Comparatively, PROCEPT BioRobotics has a beta of 0.87, meaning that its share price is 13% less volatile than the broader market.

Envista has a net margin of 2.41% compared to PROCEPT BioRobotics' net margin of -31.82%. Envista's return on equity of 7.11% beat PROCEPT BioRobotics' return on equity.

Company Net Margins Return on Equity Return on Assets
Envista2.41% 7.11% 3.91%
PROCEPT BioRobotics -31.82%-27.70%-20.29%

Envista has higher revenue and earnings than PROCEPT BioRobotics. PROCEPT BioRobotics is trading at a lower price-to-earnings ratio than Envista, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Envista$2.72B1.59$47M$0.4164.77
PROCEPT BioRobotics$308.05M3.55-$95.57M-$1.82N/A

Summary

Envista beats PROCEPT BioRobotics on 10 of the 17 factors compared between the two stocks.

How does PROCEPT BioRobotics compare to iRhythm Technologies?

PROCEPT BioRobotics (NASDAQ:PRCT) and iRhythm Technologies (NASDAQ:IRTC) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, risk, analyst recommendations, media sentiment, profitability, valuation and dividends.

iRhythm Technologies has a net margin of -3.53% compared to PROCEPT BioRobotics' net margin of -31.82%. iRhythm Technologies' return on equity of -10.26% beat PROCEPT BioRobotics' return on equity.

Company Net Margins Return on Equity Return on Assets
PROCEPT BioRobotics-31.82% -27.70% -20.29%
iRhythm Technologies -3.53%-10.26%-1.39%

In the previous week, iRhythm Technologies had 8 more articles in the media than PROCEPT BioRobotics. MarketBeat recorded 10 mentions for iRhythm Technologies and 2 mentions for PROCEPT BioRobotics. iRhythm Technologies' average media sentiment score of 0.27 beat PROCEPT BioRobotics' score of -0.55 indicating that iRhythm Technologies is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
PROCEPT BioRobotics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Negative
iRhythm Technologies
2 Very Positive mention(s)
2 Positive mention(s)
4 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

PROCEPT BioRobotics currently has a consensus target price of $37.27, indicating a potential upside of 93.93%. iRhythm Technologies has a consensus target price of $186.62, indicating a potential upside of 67.56%. Given PROCEPT BioRobotics' higher probable upside, equities analysts plainly believe PROCEPT BioRobotics is more favorable than iRhythm Technologies.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
PROCEPT BioRobotics
2 Sell rating(s)
7 Hold rating(s)
5 Buy rating(s)
1 Strong Buy rating(s)
2.33
iRhythm Technologies
1 Sell rating(s)
1 Hold rating(s)
12 Buy rating(s)
2 Strong Buy rating(s)
2.94

iRhythm Technologies has higher revenue and earnings than PROCEPT BioRobotics. iRhythm Technologies is trading at a lower price-to-earnings ratio than PROCEPT BioRobotics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
PROCEPT BioRobotics$308.05M3.55-$95.57M-$1.82N/A
iRhythm Technologies$747.14M4.90-$44.55M-$0.86N/A

PROCEPT BioRobotics has a beta of 0.87, suggesting that its share price is 13% less volatile than the broader market. Comparatively, iRhythm Technologies has a beta of 1.27, suggesting that its share price is 27% more volatile than the broader market.

89.5% of PROCEPT BioRobotics shares are held by institutional investors. 4.0% of PROCEPT BioRobotics shares are held by insiders. Comparatively, 1.0% of iRhythm Technologies shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

iRhythm Technologies beats PROCEPT BioRobotics on 13 of the 17 factors compared between the two stocks.

How does PROCEPT BioRobotics compare to Warby Parker?

Warby Parker (NYSE:WRBY) and PROCEPT BioRobotics (NASDAQ:PRCT) are both medical equipment companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, dividends, risk, media sentiment, institutional ownership, earnings, profitability and analyst recommendations.

Warby Parker has a net margin of 0.15% compared to PROCEPT BioRobotics' net margin of -31.82%. Warby Parker's return on equity of 2.30% beat PROCEPT BioRobotics' return on equity.

Company Net Margins Return on Equity Return on Assets
Warby Parker0.15% 2.30% 1.18%
PROCEPT BioRobotics -31.82%-27.70%-20.29%

In the previous week, Warby Parker had 4 more articles in the media than PROCEPT BioRobotics. MarketBeat recorded 6 mentions for Warby Parker and 2 mentions for PROCEPT BioRobotics. Warby Parker's average media sentiment score of 0.43 beat PROCEPT BioRobotics' score of -0.55 indicating that Warby Parker is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Warby Parker
2 Very Positive mention(s)
0 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
PROCEPT BioRobotics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Negative

Warby Parker has a beta of 1.91, suggesting that its stock price is 91% more volatile than the broader market. Comparatively, PROCEPT BioRobotics has a beta of 0.87, suggesting that its stock price is 13% less volatile than the broader market.

Warby Parker currently has a consensus target price of $29.82, suggesting a potential upside of 20.58%. PROCEPT BioRobotics has a consensus target price of $37.27, suggesting a potential upside of 93.93%. Given PROCEPT BioRobotics' higher probable upside, analysts plainly believe PROCEPT BioRobotics is more favorable than Warby Parker.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Warby Parker
0 Sell rating(s)
5 Hold rating(s)
10 Buy rating(s)
0 Strong Buy rating(s)
2.67
PROCEPT BioRobotics
2 Sell rating(s)
7 Hold rating(s)
5 Buy rating(s)
1 Strong Buy rating(s)
2.33

93.2% of Warby Parker shares are held by institutional investors. Comparatively, 89.5% of PROCEPT BioRobotics shares are held by institutional investors. 16.8% of Warby Parker shares are held by insiders. Comparatively, 4.0% of PROCEPT BioRobotics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Warby Parker has higher revenue and earnings than PROCEPT BioRobotics. PROCEPT BioRobotics is trading at a lower price-to-earnings ratio than Warby Parker, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Warby Parker$871.91M3.04$1.64M$0.021,236.45
PROCEPT BioRobotics$308.05M3.55-$95.57M-$1.82N/A

Summary

Warby Parker beats PROCEPT BioRobotics on 14 of the 17 factors compared between the two stocks.

Get PROCEPT BioRobotics News Delivered to You Automatically

Sign up to receive the latest news and ratings for PRCT and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PRCT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

PRCT vs. The Competition

Export
MetricPROCEPT BioRoboticsMED INSTRUMENTS IndustryMedical SectorNASDAQ Exchange
Market Cap$1.09B$7.24B$6.78B$12.28B
Dividend YieldN/A1.32%2.67%9.36%
P/E Ratio-10.5649.5127.1023.97
Price / Sales3.5583.38573.07112.38
Price / CashN/A26.9126.6847.27
Price / Book2.936.9610.666.14
Net Income-$95.57M$162.27M$3.59B$331.74M
7 Day Performance-9.43%-1.92%-1.52%-1.72%
1 Month Performance-11.51%-1.58%1.10%-1.43%
1 Year Performance-67.06%6.73%23.69%16.97%

PROCEPT BioRobotics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
PRCT
PROCEPT BioRobotics
2.7103 of 5 stars		$19.22
flat		$37.27
+93.9%		-67.1%$1.09B$308.05MN/A430
LIVN
LivaNova
1.6212 of 5 stars		$82.98
+0.5%		$80.75
-2.7%		+92.2%$4.54B$1.39B42.553,300
MMED
MiniMed Group
2.5987 of 5 stars		$16.10
+5.3%		$21.33
+32.5%		N/A$4.52B$3.10BN/A8,000
NVST
Envista
2.5916 of 5 stars		$26.23
+1.2%		$28.54
+8.8%		+37.3%$4.22B$2.72B63.9712,000
IRTC
iRhythm Technologies
4.0589 of 5 stars		$118.68
+2.2%		$187.38
+57.9%		-18.6%$3.82B$747.14MN/A2,400

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:PRCT) was last updated on 7/20/2026 by MarketBeat.com Staff.
From Our Partners
Man who Predicted Trump 2016 Win: “Prepare for Mid-Term Meltdown”
In 2016, major election models gave Hillary Clinton a 99% chance of winning - but former CIA and Pentagon advi...
Paradigm Press | Sponsoredtc pixel
Your book is inside
The "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...
Profits Run | Sponsoredtc pixel
I found Rolls-Royce at $2 - now I see the same setup again
In 2022, Karim Rahemtulla recommended Rolls-Royce under $2 - a misunderstood aerospace name the market had wri...
Monument Traders Alliance | Sponsoredtc pixel
#1 Power Grid Stock Right Now
The U.S. power grid is cracking - and one company's technology is already generating round-the-clock power in ...
Altimetry | Sponsoredtc pixel
Your withdrawal order could cost you in taxes
If you have $2M or more saved, the 4% rule points to roughly $92,000 a year - but it's a single-variable answe...
SmartAsset | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
Oxford Club Analyst’s Urgent AI Warning
Alexander Green, Chief Investment Strategist at The Oxford Club, is sharing a private presentation with a warn...
The Oxford Club | Sponsoredtc pixel
Where to Put $100 Before Trump's New Tech Law Rolls Out
The Financial Times says a new tech law puts America 'on the verge of a financial revolution.' Yahoo Finance e...
Brownstone Research | Sponsoredtc pixel